# OnCo record rndo-564 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rndo-564/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rndo-564" ;
  schema:name "RNDO-564"@en ;
  schema:description "RNDO-564 is an experimental bispecific antibody from Rondo Therapeutics, in phase 1 trials for urothelial cancer, non-small cell lung cancer and head and neck squamous cell cancer and other cancers."@en ;
  schema:url <https://onco.cc/drugs/rndo-564/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.rondotx.com/>, <https://www.rondotx.com/>, <https://clinicaltrials.gov/study/NCT07218003>, <https://clinicaltrials.gov/search?intr=RNDO-564> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Bispecific antibody (T-cell co-stimulatory engager)" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/tnbc/> ;
  onco:targets <https://onco.cc/targets/cd28/>, <https://onco.cc/targets/nectin4/> ;
  onco:companies <https://onco.cc/companies/rondo-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07218003/> .